Funda Meric-Bernstam, M.D., chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, has been elected to the National Academy of Medicine (NAM) for her contributions to precision oncology, therapeutics development and biomarker discovery, and for leading practice-changing clinical trials.
The NAM, originally established as the Institute of Medicine in 1970 by the National Academy of Sciences...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its second annual scientific...
Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population.
The University of Texas MD Anderson Cancer Center today announced an agreement to become a Women’s Cancer Partner with the Union for International...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The University of Texas MD Anderson Cancer Center today announced its first-ever academic journal, Advances in Cancer Education & Quality...
The James P. Allison Institute and the Institute for Data Science in Oncology (IDSO) at The University of Texas MD Anderson Cancer...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...